HTD1801

Phase 2Small molecule

HHighTide Biopharma Pty Ltd

HTD1801 is one of 150 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

149

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 2 DiabetesActive, not recruiting

HypercholesterolemiaActive, not recruiting

Primary Biliary CholangitisActive, not recruiting

Sclerosing CholangitisActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

HypercholesterolemiaPhase 1/Phase 2

Active, not recruiting

Primary Biliary CholangitisPhase 2

Active, not recruiting

Sclerosing CholangitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

HTD1801

HHighTide Biopharma Pty Ltd

Phase 2

5 2

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 3

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 4

Sulfonylureas

Eli Lilly

Preclinical

1 5

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 6

Acipimox

Boehringer Ingelheim

Preclinical

2 7

GLP-1

RRigshospitalet, Denmark

Preclinical

1 8

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

1 9

Routine Treatment

GSK

Preclinical

1 10

BQ123

VVanderbilt University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes5 trials

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

Completed·HHighTide Biopharma Pty Ltd·Phase 2·NCT05623189·218 enrolled

Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes

Completed·HHighTide Biopharma Pty Ltd·Phase 3·NCT06350890·408 enrolled

A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise

Completed·HHighTide Biopharma Pty Ltd·Phase 2·NCT06411275·113 enrolled

Show 2 more trials

Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Completed·HHighTide Biopharma Pty Ltd·Phase 3·NCT06353347·551 enrolled

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Completed·HHighTide Biopharma Pty Ltd·Phase 3·NCT06415773·367 enrolled

Type 2 Diabetes Mellitus1 trial

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Completed·HHighTide Biopharma Pty Ltd·Phase 2·NCT03656744·101 enrolled

Sclerosing Cholangitis1 trial

A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)

Withdrawn·HHighTide Biopharma Pty Ltd·Phase 2·NCT03678480

Hypercholesterolemia1 trial

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

Completed·HHighTide Biopharma Pty Ltd·Phase 1/2·NCT03381287·50 enrolled

Primary Biliary Cholangitis1 trial

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

Completed·HHighTide Biopharma Pty Ltd·Phase 2·NCT04604652·24 enrolled

1 more indication

Unspecified2 trials

A Study of HTD1801 in Healthy Subjects

Completed·HHighTide Biopharma Pty Ltd·Phase 1·NCT03099603·32 enrolled

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

Completed·HHighTide Biopharma Pty Ltd·Phase 2·NCT03333928·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for HTD1801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HTD1801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HTD1801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HighTide Biopharma Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHighTide Biopharma Pty Ltd

HTD1801

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes5 trials

Type 2 Diabetes Mellitus1 trial

Sclerosing Cholangitis1 trial

Hypercholesterolemia1 trial

Primary Biliary Cholangitis1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News